405 related articles for article (PubMed ID: 28077575)
1. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
[TBL] [Abstract][Full Text] [Related]
2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
3. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
4. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
5. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
7. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
8. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
9. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
[TBL] [Abstract][Full Text] [Related]
10. Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
[TBL] [Abstract][Full Text] [Related]
11. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
12. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
14. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
15. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
16. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
17. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
18. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
19. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
20. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
